First IL-17A biologic approved for polymyalgia rheumatica
-
By
-
Mouj Hijazi
-
November 17, 2026
-
2 min
Clinical Scorecard: First IL-17A inhibitor approved for polymyalgia rheumatica
At a Glance
| Category | Detail |
|---|---|
| Condition | Polymyalgia rheumatica (PMR) |
| Key Mechanisms | Secukinumab is a monoclonal antibody that targets IL-17A, a cytokine involved in inflammatory signaling. |
| Target Population | Adults with PMR who have had an inadequate response to corticosteroids or cannot tolerate corticosteroid tapering. |
| Care Setting | Treatment of adults with PMR using secukinumab in combination with a glucocorticoid taper; secukinumab may be continued alone after glucocorticoids are discontinued. |
Key Highlights
- The FDA approved secukinumab 150 mg for adults with PMR who have an inadequate response to corticosteroids or cannot tolerate corticosteroid tapering.
- In the 52-week REPLENISH trial, sustained remission occurred in 40.5% of patients receiving secukinumab 150 mg and 20.5% receiving placebo.
- Mean adjusted cumulative glucocorticoid dose through week 52 was significantly lower with secukinumab than placebo (1,683.2 mg vs 2,093 mg).
- Median time to initiation of rescue treatment for a PMR flare was 282 days with secukinumab and 157 days with placebo.
- The prescribing information warns of serious infections and inflammatory bowel disease; a fatal case of cryptococcal meningitis occurred in a secukinumab-treated patient.
Guideline-Based Recommendations
Diagnosis
Management
- According to the prescribing information, the recommended dose is secukinumab 150 mg by subcutaneous injection at weeks 0, 1, 2, 3, and 4, followed by dosing every 4 weeks.
- The prescribing information recommends use with a glucocorticoid taper; secukinumab may be continued alone after glucocorticoids are discontinued.
- The prescribing information contraindicates secukinumab in patients with serious hypersensitivity to the drug or its excipients.
Monitoring & Follow-up
- The prescribing information advises evaluating patients for tuberculosis before treatment.
- The prescribing information advises completing age-appropriate vaccinations before treatment.
Risks
- The prescribing information warns of serious infections and inflammatory bowel disease.
- In REPLENISH, serious adverse events occurred in 15.9% of patients receiving secukinumab 150 mg and 14.2% receiving placebo.
- Hypersensitivity reactions occurred in 14% of secukinumab-treated patients and 9% of placebo-treated patients; urinary tract infections occurred in 13% and 7%, respectively.
- A fatal case of cryptococcal meningitis occurred in a secukinumab-treated patient.
Patient & Prescribing Data
Adults with PMR who have had an inadequate response to corticosteroids or cannot tolerate corticosteroid tapering; REPLENISH enrolled adults with at least one relapse while tapering glucocorticoids.
The approved regimen is 150 mg subcutaneously at weeks 0, 1, 2, 3, and 4, then every 4 weeks, with a glucocorticoid taper. Secukinumab may be continued alone after glucocorticoids are discontinued.
Clinical Best Practices
- The prescribing information advises evaluating for tuberculosis and completing age-appropriate vaccinations before starting secukinumab.
- The prescribing information warns of serious infections and inflammatory bowel disease.
- The prescribing information specifies a loading schedule followed by dosing every 4 weeks, alongside a glucocorticoid taper.
Related Resources & Content
Based on findings from:
First IL-17A biologic approved for polymyalgia rheumatica
Mouj Hijazi. MDSpire News, 2026.
https://news.mdspire.com/rheumatology/articles/first-il17a-biologic-approved-for-polymyalgia-rheumatica/
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.